A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors

Annals of Oncology

Volumn 17, Issue 8, 2006, Pages 1320-1327

  Gietema, J A ^a   Hoekstra, R ^b   de Vos, F Y F L ^a   Uges, D R A ^a   van der Gaast, A ^b   Groen, H J M ^a   Loos, W J ^b   Knight, R A ^c   Carr, R A ^c   Humerickhouse, R A ^c   Eskens, F A L M ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ABBOTT LABORATORIES   (United States)

Author keywords

ABT 510; Angiogenesis inhibitor; Cisplatin; Gemcitabine; Phase I

Indexed keywords

ANGIOGENESIS INHIBITOR; CISPLATIN; GEMCITABINE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; THROMBOSPONDIN 1;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; FEASIBILITY STUDY; FEMALE; HEAD AND NECK CANCER; HEMOPTYSIS; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE EDEMA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; LEUKOPENIA; LIVER ABSCESS; LUNG NON SMALL CELL CANCER; MALE; MELANOMA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 33747883001     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl102     Document Type: Article

References (24)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
2. Lawler J. The structural and functional properties of thrombospondin. Blood 1986; 67: 1197-1209.
3. Volpert OV, Tolsma SS, Pellerin S et al. Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun 1995; 217: 326-332.
4. Jimenez B, Volpert OV, Crawford SE et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6: 41-48.
5. de Fraipont F, Nicholson AC, Feige JJ, van Meir EG. Thrombospondins and tumor angiogenesis. Trends Mol Med 2001; 7: 401-407.
6. Iruela-Arispe ML, Lombardo M, Krutzsch HC et al. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 1999; 100: 1423-1431.
7. Hoekstra R, de Vos FY, Eskens FA et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1 -mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 2005; 23: 5188-5197.
8. Gordon MS, Mendelson D, Guirguis MS et al. ABT-510, an anti-angiogenic, thrombospondin-1 (TSP-1) mimetic peptide, exhibits favorable safety profile and early signs of activity in a randomized phase 1B trial. Proc Am Soc Clin Oncol 2003; 22: 195 (Abstr 780).
9. Cobleigh MA, Langmuir VK, Sledge GW et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30: 117-124.
10. Thomas JP, Arzoomanian RZ, Alberti D et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003; 21: 223-231.
11. Zangari M, Anaissie E, Stopeck A et al, Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 2004; 10: 88-95.
12. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
13. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
14. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
15. Von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-3077.
16. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO Offset Publication No. 4, Geneva: World Health Organization 1979.
17. Siddik ZH, Boxall FE, Harrap KR. Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. Anal Biochem 1987; 163: 21-26.
18. Kuenen BC, Levi M, Meijers JC et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol 2003; 21: 2192-2198.
19. Kuenen BC, Rosen L, Smit EF et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002; 20: 1657-1667.
20. Cooney MM, Tserng KY, Makar V et al. A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. Cancer Chemother Pharmcol 2005; 55: 295-300.
21. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
22. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
23. Sandler AB, Gray R, Brahmer J et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Proc Am Soc Clin Oncol 2005; 23: LBA 4.
24. Hanna NH, Estes D, Cress A, Sidor C. Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients (pts) with advanced NSCLC: Preliminary results of a phase II trial. Proc Am Soc Clin Oncol 2004; 14: 7105.